Resistant Hypertension Workup
On this page
Direct answer
Confirm the blood pressure before chasing causes: resistant hypertension means office readings above target on three drugs including a diuretic at optimal (or best tolerated) doses — or control achieved only on four or more drugs — verified against ambulatory or home monitoring, with non-adherence excluded, since missed tablets and white-coat effect together account for more "resistance" than every secondary cause combined. Once true resistance stands, the ordered workup reviews interfering substances (NSAIDs, oral contraceptives, steroids, liquorice, sympathomimetics, alcohol), screens for secondary causes (obstructive sleep apnoea, primary aldosteronism, renal parenchymal and renovascular disease, thyroid, phaeochromocytoma, coarctation), and optimises the regimen — the PATHWAY-2 trial established low-dose spironolactone as the fourth drug, ahead of bisoprolol or doxazosin, on top of an ACE inhibitor/ARB, calcium channel blocker and thiazide-like diuretic.
What you must remember
- Definition: above-goal office blood pressure on three drugs including a diuretic at maximally tolerated doses (or controlled only on four-plus); pseudo-resistance from non-adherence, white-coat hypertension, improper cuff (small cuff on a large arm) and measurement sloppiness must be cleared first.
- Ambulatory monitoring is the arbiter: ABPM excludes the white-coat component and diagnoses nocturnal non-dipping, an independent cardiovascular risk marker.
- Drug and substance interference list: NSAIDs (sodium retention, prostaglandin inhibition — the commonest pharmacological culprit), oral contraceptive pills, corticosteroids, liquorice (apparent mineralocorticoid), nasal decongestants containing pseudoephedrine, ciclosporin, erythropoietin, alcohol excess, and cocaine or amphetamine use.
- Secondary screen targets: obstructive sleep apnoea (snoring, somnolence, the commonest association), primary aldosteronism (aldosterone-renin ratio on every true resistant patient), renal parenchymal disease (creatinine, urinalysis, ACR), renal artery stenosis (duplex in the appropriate phenotype), thyroid disease, phaeochromocytoma (metanephrines when paroxysmal symptoms), Cushing screen when the phenotype appears, coarctation (radio-femoral delay in the young).
- PATHWAY-2 answer: spironolactone 25-50 mg beats bisoprolol and doxazosin as the fourth agent for resistant hypertension — gynaecomastia and hyperkalaemia are the watch-items.
- Regimen housekeeping: switch short-acting thiazides to chlorthalidone or indapamide, dose once-nightly where appropriate, combine in single pills where cost permits, and re-check adherence honestly at every visit.
- Indian practice realities: over-the-counter NSAID use for musculoskeletal pain, non-adherence driven by cost and pill burden, and high salt plus pickle-papad dietary patterns all masquerade as resistance in Indian clinics.
Working through a resistant clinic referral
A 58-year-old teacher is referred with readings of 158/96 despite telmisartan 80 mg, amlodipine 10 mg and hydrochlorothiazide 25 mg. The first visit builds the platform: watch him take his own blood pressure with a correct cuff, review tablet counts (half his amlodipine strips sit unopened), prescribe ABPM (daytime average 148/92 — genuine resistance, non-dipping at night), and take a diet and drug history that surfaces daily diclofenac for knee pain plus heavy pickles. Replace the diclofenac with paracetamol, cap salt, switch to chlorthalidone 12.5 mg, re-assess in six weeks.
Still 150/94, he enters the secondary screen: the aldosterone-renin ratio, drawn morning and seated off interfering drugs, returns high aldosterone with suppressed renin; primary aldosteronism is confirmed by suppression testing and adrenal CT. Meanwhile spironolactone 25 mg joins as the fourth drug — appropriate even before the subtype is settled. Blood pressure lands at 132/82 by three months. The sequence — confirm, exclude interference, screen, spironolactone — is the examinable skeleton of this topic.
Where students slip
The reflex error is launching into "phaeochromocytoma workup" before confirming the blood pressure is real: the first investigation in a suspected resistant patient is ambulatory (or home) monitoring, and the first intervention is adherence assessment — MCQs plant the endocrine answer early to catch the over-eager. Second, the NSAID blind spot: a stem mentioning chronic knee or back pain with escalating antihypertensives is pointing at the painkillers, and stopping them is the "next best step" more often than adding a drug. Third, PATHWAY-2 knowledge: when the options list spironolactone, bisoprolol and doxazosin as add-on choices, spironolactone is the evidence-backed pick, and quoting it with the hyperkalaemia caveat reads like clinical experience rather than guesswork. Finally, "resistant plus hypokalaemia plus alkalosis" steers to aldosteronism, and "resistant plus snoring plus somnolence" to sleep apnoea — two one-line recognitions worth a mark each.
Frequently asked questions
What defines resistant hypertension?
Blood pressure above goal on three antihypertensive drugs including a diuretic at optimal doses, or control requiring four or more drugs, after pseudo-resistance has been excluded.
Which test should precede all secondary workup?
Ambulatory blood pressure monitoring (with home readings as an adjunct) to confirm true out-of-office hypertension and detect non-dipping, alongside an honest adherence review.
Why are NSAIDs a classic cause of resistance?
They promote sodium and water retention and inhibit prostaglandin-mediated vasodilatation, blunting the effect of antihypertensives — stopping them often restores control.
Which drug is the evidence-based fourth agent?
Low-dose spironolactone (25-50 mg), which outperformed bisoprolol and doxazosin in the PATHWAY-2 trial on top of standard triple therapy.
Which secondary cause should be screened in every true resistant patient?
Primary aldosteronism via the plasma aldosterone-to-renin ratio — the commonest curable secondary cause, and prevalent well beyond the textbook hypokalaemic minority.